Early Rebiopsy is Not Necessary for Patients Prior Detected Atypical Small Acinar Proliferation (ASAP) at 12 Core TRUS Guided Prostate Biopsy and Candidate for Active Surveillance
SIU Academy®. Soydan H. 09/09/13; 32890; UP.237
Topic: Active surveillance
Abstract
Discussion Forum (0)
Rate & Comment (0)
Early Rebiopsy is Not Necessary for Patients' Prior Detected Atypical
Small Acinar Proliferation (ASAP) at 12 Core TRUS Guided Prostate Biopsy
and Candidate for Active Surveillance
Introduct?on and Object?ves: To review rebiopsy and long-term follow-up
results of patients' prior detected atypical small acinar proliferation
(ASAP) and investigate whether these patients are candidate for active
surveillance.
Mater?als and Methods: We retrospectively reviewed the TRUS guided at
least 12 core prostate biopsy results. We examined age, serum PSA level,
digital rectal examination (DRE), rebiopsy and follow-up results and
treatments of patients who detected ASAP and investigated whether there
is any difference between the patients with tumor and no tumor at
rebiopsy.
Results: Between 2007-2012, 926 patiens underwent prostate biopsy in our
clinic. ASAP was detected in 20 (2,2%) of these patients. The average
age of patients was 62 (67-79) years. The mean PSA level is 6.67 ng/ml
(1.5 to 23). Three patients had DRE abnormality, while 17 patients had
no abnormality. Eighteen patients were detected with ASAP at their first
biopsies. In one patient ASAP was detected after one benign biopsy. In
another patient ASAP was detected after two benign biopsies. The
following 18 core control biopsy results were reported benign for these
two patients. Considering the patients with ASAP detected at their first
biopsy, 15 of them underwent second biopsy. Among the 15 patients, 9 of
them reported as benign, 6 of them reported as prostate adenocarcinoma:
4 one core Gleason score 3+3, 1 two core positive Gleason score 3+3, 1
one core positive Gleason score 4+3. The mean PSA level of the patients
with tumor is 5.43ng/ml (3.7 to 7.41). Except one, all patients with
tumor had no DRE abnormality. Four patients with prostate cancer has
chosen active surveillance. They are followed for an average of three
years. On the control biopsies, except for one patient had no tumor. The
biopsy results of the patient who has detected tumor on the control
biopsy was similar to his first biopsy. Radical prostatectomy is applied
to 1 patient and his pathologic result was pT2, Gleason score 3 +3,
tumor volume was less than 1% of the prostate volume. We proposed
radical prostatectomy to the patient whose biopsy result was reported as
gleason 4+3 prostate adenocarsinoma.
6
J
L
`
-
p
q
�
�
j l 6
h?P�CJ ^J : Although we have limited number of patients, applying late
biopsy instead of early does not effect the oncologic outcomes adversly
in patients detected ASAP in their first biopsies appropriate for active
surveillance.
Click here to see the original abstract file
Small Acinar Proliferation (ASAP) at 12 Core TRUS Guided Prostate Biopsy
and Candidate for Active Surveillance
Introduct?on and Object?ves: To review rebiopsy and long-term follow-up
results of patients' prior detected atypical small acinar proliferation
(ASAP) and investigate whether these patients are candidate for active
surveillance.
Mater?als and Methods: We retrospectively reviewed the TRUS guided at
least 12 core prostate biopsy results. We examined age, serum PSA level,
digital rectal examination (DRE), rebiopsy and follow-up results and
treatments of patients who detected ASAP and investigated whether there
is any difference between the patients with tumor and no tumor at
rebiopsy.
Results: Between 2007-2012, 926 patiens underwent prostate biopsy in our
clinic. ASAP was detected in 20 (2,2%) of these patients. The average
age of patients was 62 (67-79) years. The mean PSA level is 6.67 ng/ml
(1.5 to 23). Three patients had DRE abnormality, while 17 patients had
no abnormality. Eighteen patients were detected with ASAP at their first
biopsies. In one patient ASAP was detected after one benign biopsy. In
another patient ASAP was detected after two benign biopsies. The
following 18 core control biopsy results were reported benign for these
two patients. Considering the patients with ASAP detected at their first
biopsy, 15 of them underwent second biopsy. Among the 15 patients, 9 of
them reported as benign, 6 of them reported as prostate adenocarcinoma:
4 one core Gleason score 3+3, 1 two core positive Gleason score 3+3, 1
one core positive Gleason score 4+3. The mean PSA level of the patients
with tumor is 5.43ng/ml (3.7 to 7.41). Except one, all patients with
tumor had no DRE abnormality. Four patients with prostate cancer has
chosen active surveillance. They are followed for an average of three
years. On the control biopsies, except for one patient had no tumor. The
biopsy results of the patient who has detected tumor on the control
biopsy was similar to his first biopsy. Radical prostatectomy is applied
to 1 patient and his pathologic result was pT2, Gleason score 3 +3,
tumor volume was less than 1% of the prostate volume. We proposed
radical prostatectomy to the patient whose biopsy result was reported as
gleason 4+3 prostate adenocarsinoma.
6
J
L
`
-
p
q
�
�
j l 6
h?P�CJ ^J : Although we have limited number of patients, applying late
biopsy instead of early does not effect the oncologic outcomes adversly
in patients detected ASAP in their first biopsies appropriate for active
surveillance.
Click here to see the original abstract file
Early Rebiopsy is Not Necessary for Patients' Prior Detected Atypical
Small Acinar Proliferation (ASAP) at 12 Core TRUS Guided Prostate Biopsy
and Candidate for Active Surveillance
Introduct?on and Object?ves: To review rebiopsy and long-term follow-up
results of patients' prior detected atypical small acinar proliferation
(ASAP) and investigate whether these patients are candidate for active
surveillance.
Mater?als and Methods: We retrospectively reviewed the TRUS guided at
least 12 core prostate biopsy results. We examined age, serum PSA level,
digital rectal examination (DRE), rebiopsy and follow-up results and
treatments of patients who detected ASAP and investigated whether there
is any difference between the patients with tumor and no tumor at
rebiopsy.
Results: Between 2007-2012, 926 patiens underwent prostate biopsy in our
clinic. ASAP was detected in 20 (2,2%) of these patients. The average
age of patients was 62 (67-79) years. The mean PSA level is 6.67 ng/ml
(1.5 to 23). Three patients had DRE abnormality, while 17 patients had
no abnormality. Eighteen patients were detected with ASAP at their first
biopsies. In one patient ASAP was detected after one benign biopsy. In
another patient ASAP was detected after two benign biopsies. The
following 18 core control biopsy results were reported benign for these
two patients. Considering the patients with ASAP detected at their first
biopsy, 15 of them underwent second biopsy. Among the 15 patients, 9 of
them reported as benign, 6 of them reported as prostate adenocarcinoma:
4 one core Gleason score 3+3, 1 two core positive Gleason score 3+3, 1
one core positive Gleason score 4+3. The mean PSA level of the patients
with tumor is 5.43ng/ml (3.7 to 7.41). Except one, all patients with
tumor had no DRE abnormality. Four patients with prostate cancer has
chosen active surveillance. They are followed for an average of three
years. On the control biopsies, except for one patient had no tumor. The
biopsy results of the patient who has detected tumor on the control
biopsy was similar to his first biopsy. Radical prostatectomy is applied
to 1 patient and his pathologic result was pT2, Gleason score 3 +3,
tumor volume was less than 1% of the prostate volume. We proposed
radical prostatectomy to the patient whose biopsy result was reported as
gleason 4+3 prostate adenocarsinoma.
6
J
L
`
-
p
q
�
�
j l 6
h?P�CJ ^J : Although we have limited number of patients, applying late
biopsy instead of early does not effect the oncologic outcomes adversly
in patients detected ASAP in their first biopsies appropriate for active
surveillance.
Click here to see the original abstract file
Small Acinar Proliferation (ASAP) at 12 Core TRUS Guided Prostate Biopsy
and Candidate for Active Surveillance
Introduct?on and Object?ves: To review rebiopsy and long-term follow-up
results of patients' prior detected atypical small acinar proliferation
(ASAP) and investigate whether these patients are candidate for active
surveillance.
Mater?als and Methods: We retrospectively reviewed the TRUS guided at
least 12 core prostate biopsy results. We examined age, serum PSA level,
digital rectal examination (DRE), rebiopsy and follow-up results and
treatments of patients who detected ASAP and investigated whether there
is any difference between the patients with tumor and no tumor at
rebiopsy.
Results: Between 2007-2012, 926 patiens underwent prostate biopsy in our
clinic. ASAP was detected in 20 (2,2%) of these patients. The average
age of patients was 62 (67-79) years. The mean PSA level is 6.67 ng/ml
(1.5 to 23). Three patients had DRE abnormality, while 17 patients had
no abnormality. Eighteen patients were detected with ASAP at their first
biopsies. In one patient ASAP was detected after one benign biopsy. In
another patient ASAP was detected after two benign biopsies. The
following 18 core control biopsy results were reported benign for these
two patients. Considering the patients with ASAP detected at their first
biopsy, 15 of them underwent second biopsy. Among the 15 patients, 9 of
them reported as benign, 6 of them reported as prostate adenocarcinoma:
4 one core Gleason score 3+3, 1 two core positive Gleason score 3+3, 1
one core positive Gleason score 4+3. The mean PSA level of the patients
with tumor is 5.43ng/ml (3.7 to 7.41). Except one, all patients with
tumor had no DRE abnormality. Four patients with prostate cancer has
chosen active surveillance. They are followed for an average of three
years. On the control biopsies, except for one patient had no tumor. The
biopsy results of the patient who has detected tumor on the control
biopsy was similar to his first biopsy. Radical prostatectomy is applied
to 1 patient and his pathologic result was pT2, Gleason score 3 +3,
tumor volume was less than 1% of the prostate volume. We proposed
radical prostatectomy to the patient whose biopsy result was reported as
gleason 4+3 prostate adenocarsinoma.
6
J
L
`
-
p
q
�
�
j l 6
h?P�CJ ^J : Although we have limited number of patients, applying late
biopsy instead of early does not effect the oncologic outcomes adversly
in patients detected ASAP in their first biopsies appropriate for active
surveillance.
Click here to see the original abstract file
Code of conduct/disclaimer available in General Terms & Conditions
{{ help_message }}
{{filter}}